FDA recall, , Moderate risk
Zoladex (Goserelin) Implant
Zoladex (goserelin) implant was exposed to non-temperature-controlled conditions for 25.5 hours.
Summary by Recall Canary from the FDA notice
What happened
TerSera Therapeutics LLC, of Deerfield, Illinois, recalled Zoladex (goserelin) implant, 3.6 mg, a single-use syringe packaged in a carton, after the product sat in a non-temperature-controlled FedEx trailer at ambient outdoor conditions for 25.5 hours. The recall began August 31, 2026, and was added to the FDA's Enforcement Report on September 28, 2026.
The product was distributed nationwide in the USA. The recall affected 296 cartons of the implant, which is manufactured for TerSera by AstraZeneca UK Limited, Macclesfield, England, and is a product of Switzerland.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Match the NDC and lot code listed under your product.
An NDC (National Drug Code) is usually printed on the drug's label.
Zoladex (goserelin) implant
- NDC
- 70720-950-36
- Lot code
- YN0099
Recall details
- Company began the recall
- Sold in
USA Nationwide
- Company
- TerSera Therapeutics LLCDeerfield, Illinois
- Hazard
- Processing problem
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 99795
- Recall number
- D-0875-2026
- Quantity recalled
- 296 cartons
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
Listed on Recall Canary
Summary updated
In FDA's weekly enforcement report
